According to a recent LinkedIn post from Infinity Bio Inc, the company is participating in IMMUNOLOGY2026 in Boston and inviting attendees to visit its booth and a scientific poster session. The post highlights work titled “Decoding the Antibody Reactome at Scale with Novel Antigen Display Technology to Decipher Immune History,” presented by team member Katy Shaw-Saliba.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The content suggests Infinity Bio Inc is emphasizing its capabilities in antibody reactomics and antigen display technologies, areas that are relevant to immune profiling and therapeutic discovery. For investors, visible engagement at a major immunology meeting may indicate ongoing R&D momentum and efforts to build scientific credibility, which could support future partnership, licensing, or customer opportunities in the immunology and biotech tools markets.